Omicron SARS-CoV-2 variant: An observational study from a hospital in Southern India
, , , , et | 23 août 2022
À propos de cet article
Publié en ligne: 23 août 2022
Pages: 79 - 90
Reçu: 09 mai 2022
Accepté: 01 juil. 2022
DOI: https://doi.org/10.2478/acm-2022-0010
© 2022 Rajesh Jayanandan et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Distribution of study subjects based on symptoms and treatment details
| Characteristic | Frequency (%) |
|---|---|
| Symptomatic | 149 (73.4) |
| Asymptomatic | 54 (26.6) |
| Fever | 114 (76.5) |
| Cough | 72 (48.3) |
| Myalgia | 29 (19.5) |
| Running nose | 28 (18.8) |
| Sore throat | 26 (17.4) |
| Fatigue | 20 (13.4) |
| Headache | 20 (13.4) |
| Breathlessness | 12 (8.0) |
| Sneezing | 10 (6.7) |
| Chills | 7 (4.7) |
| Diarrhoea | 7 (4.7) |
| Outpatient | 114 (56.1) |
| In-patient | 89 (43.8) |
| Mild case | 193 (95.1) |
| Moderate case | 8 (3.9) |
| Severe case | 2 (1.0) |
| Oxygen support required | 10 (4.9) |
| Oxygen support not required | 193 (95.1) |
| Simple face mask | 8 (80.0) |
| CPAP | 2 (20.0) |
| Treated in Home isolation | 134 (66.0) |
| Discharged from IP ward | 60 (29.6) |
| Referred to other Hospital | 7 (3.4) |
| Died | 2 (1.0) |
Comparison of duration of last dose of COVID-19 vaccine taken and RT-PCR Positivity with SGTF between partially and completely vaccinated subjects (n = 156)
| Vaccination status | Type of vaccine | Mean (SD) | 95% CI of Mean | Median | Mean difference (95% CI of Mean difference) | P value |
|---|---|---|---|---|---|---|
| Partially vaccinated (n = 31) | Covaxin (n = 6) | 115 (72 days) | 39, 191 days | 121 days | -11 days (-75, 52 days) | 0.960 |
| Covishield (n = 25) | 126 (67 days) | 98, 154 days | 114 days | |||
| Completely vaccinated (n = 125) | Covaxin (n = 44) | 186 (82 days) | 162, 210 days | 195 days | 55 days (25, 85 days) | |
| Covishield (n = 81) | 131 (79 days) | 114, 148 days | 113 days |
Comparison of interval between two doses of COVID vaccine taken among completely vaccinated RTPCR Positive SGTF subjects (n = 125)
| Type of Vaccine | Mean (SD) | 95% CI of Mean | Median (IQR) | Mean difference (95% CI of Mean difference) | P value |
|---|---|---|---|---|---|
| Covaxin (n = 44) | 48 (25) days | 40, 55 days | 33 (30, 60) days | - 37 (-50, -24) days | |
| Covishield (n = 81) | 85 (39) days | 76, 94 days | 89 (51, 97) days |
Association between COVID-19 vaccination status of subjects and their symptom status, course of treatment and supplemental oxygen requirement (N = 203)
| Variable | Vaccinated n = 158 | Unvaccinated n = 45 | P value | Odds Ratio [95% CI] |
|---|---|---|---|---|
| Symptomatic | 116 (73.4) | 33 (73.3) | 0.991 | 1.004 |
| Asymptomatic | 42 (26.6) | 12 (26.7) | (0.475, 2.124) | |
| Outpatient | 99 (62.7) | 15 (33.3) | 3.356 | |
| In-patient | 59 (37.3) | 30 (66.7) | (1.669, 6.748) | |
| Required | 4 (2.5) | 6 (13.3) | 0.169 | |
| Not required | 154 (97.5) | 39 (86.7) | (0.045, 0.628) | |
Distribution of Study subjects based on treatment details
| Treatment details | Frequency (%) |
|---|---|
| Vaccinated | 158 (77.8) |
| Unvaccinated | 45 (22.2) |
| Covaxin | 50 (31.7) |
| Covishield | 106 (67.0) |
| Other vaccines | 2 (1.3) |
| One Dose (Partially vaccinated) | 32 (20.3) |
| Two Doses (Completely vaccinated) | 126 (79.7) |
Distribution of study subjects based on Socio-demographic characteristics
| Characteristic (N = 203) | Frequency (%) |
|---|---|
| 20 years and below | 19 (9.4) |
| 21 – 40 years | 79 (38.9) |
| 41 – 60 years | 78 (38.4) |
| 61 – 80 years | 24 (11.8) |
| Above 80 years | 3 (1.5) |
| Male | 129 (63.5) |
| Female | 74 (36.5) |
| Comorbid | 39 (19.2) |
| Non-comorbid | 164 (80.8) |
| Present | 29 (14.3) |
| Absent | 174 (85.7) |
| Present | 16 (7.9) |
| Absent | 173 (85.2) |
| Not sure | 14 (6.9) |
| 5 months and below | 3 (18.8) |
| 6 – 10 months | 10 (62.5) |
| 11 – 15 months | 2 (12.5) |
| 16 – 20 months | 1(6.2) |